PEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good

Similar documents
SIR- RFS Journal Primer

Hepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center

Hepatocellular Carcinoma. Markus Heim Basel

Surveillance for Hepatocellular Carcinoma

Hepatocellular Carcinoma Surveillance

Hepatocellular Carcinoma: Diagnosis and Management

Interventional Radiology in Liver Cancer. Nakarin Inmutto MD

Liver Perfusion Analysis New Frontiers in Dynamic Volume Imaging. Case Study Brochure Chang Gung Memorial Hospital.

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center

Hepatocellular carcinoma

Liver Directed Therapy for Hepatocellular Carcinoma

Percutaneous ablation: indications, techniques and results

Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging

Disclosure. Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report:

Management of HepatoCellular Carcinoma

Stereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V.

Advances in percutaneous ablation for hepatocellular carcinoma

Reconsidering Liver Transplantation for HCC in a Era of Organ shortage

The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page

Staging & Current treatment of HCC

9th Paris Hepatitis Conference

Addictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis

SEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA

Timothy L. Miao 1, Ania Z. Kielar 2,3, Rebecca M. Hibbert 2, Nicola Schieda 2,3

EASL-EORTC Guidelines

Radiation Therapy for Liver Malignancies

Guidelines for SIRT in HCC An Evolution

Hepatocellular Carcinoma in Qatar

Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC

Liver Cancer: Diagnosis and Treatment Options

The Egyptian Journal of Hospital Medicine (October 2017) Vol. 69 (4), Page

RETHINKING OUR APPROACH TO INTERMEDIATE-SIZE HCC

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Tumor incidence varies significantly, depending on geographical location.

Liver transplantation: Hepatocellular carcinoma

Locoregional Therapy for Hepatoma

Radiofrequency Ablation versus Microwave Ablation in HCC and Liver Metastases

Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology

Ruolo della interventistica per le secondarietà epatiche e di altre sedi

6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration

OPTIMA Phase III Clinical Trial: Study Design and Protocols

Paul Martin MD FACG. University of Miami

HCC: Is it an oncological disease? - No

Effective Health Care Program

MRI for HCC surveillance and reporting: LI-RADS. Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA

9/10/2018. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? DISCLOSURES

Clinical Commissioning Policy Proposition:

3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.

Corporate Medical Policy

RFA-based Combination Therapy 肝病研究中心, 肝臟科 林口長庚醫院, 長庚醫學大學 (CHANG GUNG MEMORIAL HOSPITAL, LINKUO) 林成俊 (CHEN-CHUN LIN)

Liver resection for HCC

Locoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates

Early disseminated recurrence after liver resection in solitary hepatocellular carcinoma

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Pamplona, junio de Futuro de la Hepatología: Cáncer Hepático. Bruno Sangro Clínica Universidad de Navarra. IDISNA. CIBERehd.

WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?

LIVER IMAGING TIPS IN VARIOUS MODALITIES. M.Vlychou, MD, PhD Assoc. Professor of Radiology University of Thessaly

Embolotherapy for Cholangiocarcinoma: 2016 Update

MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC

CAPGAN th Scientific Meeting of Commonwealth Association of Paediatric, Gastroenterology and Nutrition 2-4 October 2015 : New Delhi, India

RESEARCH ARTICLE. Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy

Title: Dengue Score: a proposed diagnostic predictor of pleural effusion and/or ascites in adult with dengue infection

Citation for published version (APA): Hompes, D. N. M. (2013). Advanced colorectal cancer: Exploring treatment boundaries.

Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies

2009 Practice Guidelines for the Management of Hepatocellular Carcinoma

Despite recent advances in the care of patients with

Hepatocellular carcinoma in Sri Lanka - where do we stand?

Understanding Liver Cancer: A Tale of Two Diseases

The Focal Hepatic Lesion: Radiologic Assessment

State-of-the-art minimally invasive interventions for liver tumors

Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma

doi: /hepr Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)

Liver Tumors. Prof. Dr. Ahmed El - Samongy

The Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study

Hepatocellular Carcinoma: Transplantation, Resection or Ablation?

Treatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center

Kit-Fai Lee, Charing C. N. Chong, Anthony K. W. Fong, Andrew K. Y. Fung, Hon-Ting Lok, Yue-Sun Cheung, John Wong, Paul B. S. Lai

A Metastatic Adrenal Tumor from a Hepatocellular Carcinoma: Combination Therapy with Transarterial

Survival Difference between Surgery Versus Non-Surgery for the Treatment of Hepatocellular Carcinoma Patients at Liver Centre, Malaysia

Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma

Hepatocellular carcinoma: from guidelines to individualized treatment

Hepatocellular Carcinoma (HCC)

TRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD

Learning Objectives. After attending this presentation, participants will be able to:

Individualized laparoscopic B-ultrasound-guided microwave ablation for multifocal primary liver cancer

NCCN TRENDS DEMOGRAPHICS. Results: March 2014 LIVER CANCER. Distribution of Respondent Types (n = 581) Page 1

TREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD

Thrombocytopenia and Chronic Liver Disease

Down-Staging of Hepatocellular Carcinoma via External-Beam Radiotherapy With Subsequent Liver Transplantation: A Case Report

Interventional Radiologic Treatment of Hepatocellular Carcinoma

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

NAACCR Webinar Series 1

Prognostic factors after hepatic resection for the single hepatocellular carcinoma larger than 5 cm

HCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation

Treatment of HCC in real life-chinese perspective

Clinical Policy Bulletin: Ablation of Hepatic Lesions

Liver 6/5/14. Collecting Cancer Data: Liver NAACCR Webinar Series. June 5, 2014

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT

Case Studies of Laser Ablation for Liver Tumors

Transcription:

Reviewer s code: 03656588 Reviewer s country: China Date reviewed: 2017-06-08 [ ] Grade A: Excellent [ Y] Accept [ ] Grade B: Very good [ ] High priority for [ Y] Grade C: Good language [ ] Major revision 1) In this retrospective study, the authors evaluated the relationship between the location of the HCC (in particular, the location close to the peripheral or hepatic portal portion of the liver) and the efficacy of TACE. It is an interesting study on TACE for HCC. 2) The results demonstrated that a significant difference between the location of HCC and efficacy of TACE existed only in the Child-Pugh grade A patients. When HCC is located in the peripheral area in the right lobe or medial segment, TACE is much more suitable for treatment. when HCC is located in the central area in the right lobe or medial segment, an early combination of local ablation therapy (such as radiofrequency ablation and percutaneous ethanol injection) with TACE may be efficacious. It is very important guidance for clinical doctors to select the TACE for HCC. 3) But there were very few HCC nodules in the caudate lobe in the study, it need further supplemental data and compare the location of HCC and efficacy of TACE in the caudate lobe. 4) I suggest that 1

the manuscript can be published in the form of retrospective study in World J Gastroenterology after data are supplemented. 2

Reviewer s code: 02527808 Reviewer s country: Egypt Date reviewed: 2017-06-12 [ Y] Grade A: Excellent [ ] Accept [ ] Grade B: Very good [ Y] High priority for [ ] Grade C: Good language [ ] Major revision The study is interesting as regard the evaluation of the relationship between the location of hepatocellular carcinoma (HCC) and efficacy of transarterial chemoembolization (TACE).as those critically ill patients need right option for treatment. But the main defect is the small number of cases in the subgroups below statistical significance as in table 2. Language editing is needed as spacing between words need revision e.g group,withno significant difference inthe lateral segment. In Child Pugh B, median location ratio of HCC in each lobe and segment was not significantly different between the two groups. Therefore,improved TACE efficacymaybe obtained for HCC in the peripheral zone of the right lobe and medial segment in Child Pugh A patients. 3

Reviewer s code: 02530754 Reviewer s country: Spain Date reviewed: 2017-06-22 [ ] Grade A: Excellent [ ] Accept [ Y] Grade B: Very good [ ] High priority for [ ] Grade C: Good language [ Y] Major revision The manuscript by Miki et al is a retrospective analysis which analyzed the influence of HCC location on tumor radiological response after TACE. The manuscript is informative and provides interesting insights. The authors are kindly invited to consider the following recommendations: 1- Please clarify whether the concept of HCC location ratio is empirically proposed by the authors, or has been validated in previous studies. In the latter scenario, please provide references. 2- Conventionally, p values <0.001 are presented as such. Please avoid expressions like 7.5x10-5 (see for instance line 13 in the abstract). 3- Among the inclusion criteria, the following can be read: MDCT or MRI performed before TACE and at least 6 months after TACE. Does it mean that the interval between TACE and evaluation of radiological response varied among the included patients? 4- The authors state that the median recurrence time was 2 months, but evaluation of radiological response was performed from 6 months 4

onwards. If a radiological surveillance was protocolized earlier after TACE, it should be described in methods. 5- Some demographic features are displayed in methods. Please, move this information to the results section. 6- The term ratio in epidemiology is a time-dependent concept, which may be cause misunderstanding in the present paper. I would recommend using location coefficient instead of location ratio. 7- Although the reader may be able to infer that an increased location ratio actually refer to a more peripheral nodule, I would recommend to specify this information in methods to avoid confusion. 8- The potential role of HCC imaging and histological features as potential confounding factors in the present study is unclear. Are those tumors with increased location coefficient also more advanced, less differentiated or associate microvascular invasion more frequently? In order to clarify this important caveat, I would recommend the authors to run a multivariate logistic regression analysis including tumor features, location coefficient and Child-Pugh status. These new results would greatly increase the strength of the evidence. 9- The manuscript would benefit from minor English. 10- In table 3, please provide standard deviations for location coefficient values. In addition, p values should be corrected as stated above in comment number 2. 5